EP4228613A4 - ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES - Google Patents

ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES Download PDF

Info

Publication number: EP4228613A4
Authority: EP; European Patent Office
Prior art keywords: medium chain; chain triglycerides; cannabinoid formulation; tocopheryl phosphates; oral cannabinoid
Prior art date: 2020-10-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21881370.7A

Other languages

German (de)

French (fr)

Other versions

EP4228613A1 (en

Inventor

Paul Gavin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Avecho Biotechnology Ltd

Original Assignee

Avecho Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-10-19

Filing date

2021-10-18

Publication date

2024-10-23

2020-10-19 Priority claimed from AU2020903781A external-priority patent/AU2020903781A0/en

2021-10-18 Application filed by Avecho Biotechnology Ltd filed Critical Avecho Biotechnology Ltd

2023-08-23 Publication of EP4228613A1 publication Critical patent/EP4228613A1/en

2024-10-23 Publication of EP4228613A4 publication Critical patent/EP4228613A4/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP21881370.7A 2020-10-19 2021-10-18 ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES Pending EP4228613A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AU2020903781A AU2020903781A0 (en)		2020-10-19	Pharmaceutical formulations
PCT/AU2021/051212 WO2022082257A1 (en)	2020-10-19	2021-10-18	Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates

Publications (2)

Publication Number	Publication Date
EP4228613A1 EP4228613A1 (en)	2023-08-23
EP4228613A4 true EP4228613A4 (en)	2024-10-23

Family

ID=81291044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21881370.7A Pending EP4228613A4 (en)	2020-10-19	2021-10-18	ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES

Country Status (6)

Country	Link
US (1)	US20230381208A1 (en)
EP (1)	EP4228613A4 (en)
AU (1)	AU2021366254A1 (en)
CA (1)	CA3195938A1 (en)
IL (1)	IL302169A (en)
WO (1)	WO2022082257A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116583272A (en)	2020-10-19	2023-08-11	埃维科生物技术有限公司	Oral cannabinoid formulations comprising tocopheryl phosphate and long-chain triglycerides or long-chain fatty acids
WO2024189151A1 (en) *	2023-03-14	2024-09-19	Dsm Ip Assets B.V.	Cannabinoid formulations
WO2025129244A1 (en) *	2023-12-19	2025-06-26	Avecho Biotechnology Limited	Cannabinoid formulations providing rapid onset of pharmaceutical and recreational effects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3193834B1 (en) *	2014-09-18	2020-04-01	Virun, Inc.	Pre-spray emulsions and powders containing non-polar compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
AUPR684801A0 (en)	2001-08-06	2001-08-30	Vital Health Sciences Pty Ltd	Supplement therapy
AU2002950713A0 (en)	2002-08-09	2002-09-12	Vital Health Sciences Pty Ltd	Carrier
WO2004064831A1 (en)	2003-01-17	2004-08-05	Vital Health Sciences Pty Ltd	Compounds having anti-proliferative properties
DK1720551T3 (en)	2004-03-03	2011-05-16	Vital Health Sciences Pty Ltd	Alkaloid formulations
CA2575587C (en)	2004-08-03	2014-06-17	Vital Health Sciences Pty Ltd	Carrier for enteral administration
US20090239827A1 (en)	2005-03-03	2009-09-24	Esra Ogru	Compounds having lipid lowering properties
CA2599424A1 (en)	2005-03-03	2006-09-08	Vital Health Sciences Pty Ltd	Compounds having anti-cancer properties
PT1903866E (en)	2005-11-07	2016-06-09	Murty Pharmaceuticals Inc	IMPROVED TETRA-HYDROCANABINOL DISTRIBUTION
US20090005348A1 (en)	2005-12-23	2009-01-01	Vital Health Sciences Pty Ltd	Compounds Having Cytokine Modulating Properties
US9693574B2 (en)	2013-08-08	2017-07-04	Virun, Inc.	Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
CN114712308A (en)	2015-12-09	2022-07-08	磷肌酸有限公司	Pharmaceutical preparation
EP3558903B1 (en)	2016-12-21	2024-07-03	Avecho Biotechnology Limited	Process for phosphorylating a complex alcohol
US10687541B2 (en)	2017-10-11	2020-06-23	Jesse Windrix	Emulsified oils and blends
AU2019300877A1 (en)	2018-07-09	2021-03-04	New Age Nanotech Llc	Stabilized formulations of cannabinoid compositions
WO2020092451A1 (en)	2018-10-29	2020-05-07	Keto Patent Group, Inc.	Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
US20210046438A1 (en)	2019-08-15	2021-02-18	Steven Paul Hansen	Surfactant Compositions and Methods for Emulsifying Cannabinoid Extracts as a Nano-Emulsion Material
US11998632B2 (en)	2019-09-05	2024-06-04	Avicanna Inc.	Oral cannabinoid compositions and methods for treating neuropathic pain
EP4028059B1 (en)	2019-09-09	2025-12-24	Cardiol Therapeutics Inc.	Stable medicinal cannabidiol compositions
CN110638756B (en)	2019-11-07	2021-10-08	辰风天然本草(北京)科技有限公司	A kind of composition containing cannabidiol and preparation method thereof
EP3871510A1 (en)	2020-02-25	2021-09-01	Tapperwein Collection AG	Medium chain triglyceride based oil phase in water microemulsions

2021
- 2021-10-18 WO PCT/AU2021/051212 patent/WO2022082257A1/en not_active Ceased
- 2021-10-18 US US18/249,647 patent/US20230381208A1/en active Pending
- 2021-10-18 EP EP21881370.7A patent/EP4228613A4/en active Pending
- 2021-10-18 IL IL302169A patent/IL302169A/en unknown
- 2021-10-18 AU AU2021366254A patent/AU2021366254A1/en active Pending
- 2021-10-18 CA CA3195938A patent/CA3195938A1/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3193834B1 (en) *	2014-09-18	2020-04-01	Virun, Inc.	Pre-spray emulsions and powders containing non-polar compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "LifeSense Product C8 KetoMCT solubilizes CBD - LifeSense Products", LIFESENSE PRODUCTS, 19 February 2020 (2020-02-19), pages 1 - 11, XP055926411, Retrieved from the Internet <URL:https://lifesenseproducts.com/blogs/news/lifesense-product-c8-ketomct-solubilizes-cbd> [retrieved on 20220531] *
CHERNIAKOV IRINA ET AL: "Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 8 September 2017 (2017-09-08), pages 1 - 7, XP085292686, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.011 *
IZGELOV DVORA ET AL: "The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 580, 6 March 2020 (2020-03-06), XP086127085, ISSN: 0378-5173, [retrieved on 20200306], DOI: 10.1016/J.IJPHARM.2020.119201 *
PHAM ANNA C ET AL: "A new lipid excipient, phosphorylated tocopherol mixture, TPM enhances the solubilisation and oral bioavailability of poorly water soluble CoQ10in a lipid formulation", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 268, 31 October 2017 (2017-10-31), pages 400 - 406, XP085300197, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.10.039 *
See also references of WO2022082257A1 *

Also Published As

Publication number	Publication date
US20230381208A1 (en)	2023-11-30
IL302169A (en)	2023-06-01
AU2021366254A1 (en)	2023-06-08
WO2022082257A1 (en)	2022-04-28
EP4228613A1 (en)	2023-08-23
CA3195938A1 (en)	2022-04-28

Legal Events

Date	Code	Title	Description
2022-04-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-07-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-07-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-08-23	17P	Request for examination filed	Effective date: 20230519
2023-08-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-01-24	DAV	Request for validation of the european patent (deleted)
2024-01-24	DAX	Request for extension of the european patent (deleted)
2024-10-23	A4	Supplementary search report drawn up and despatched	Effective date: 20240925
2024-10-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 47/22 20060101ALI20240919BHEP Ipc: A61K 47/14 20170101ALI20240919BHEP Ipc: A61K 31/352 20060101ALI20240919BHEP Ipc: A61K 31/192 20060101ALI20240919BHEP Ipc: A61K 31/05 20060101AFI20240919BHEP

Publication	Publication Date	Title
EP4228613A4 (en)	2024-10-23	ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES
EP3909281A4 (en)	2022-10-26	EU TO EU INTERFERENCE MEASUREMENT AND REPORTING
EP3898840A4 (en)	2022-11-02	HYDROGEL COMPOSITIONS BASED ON POLYSACCHARIDES AND ZWITTERIONIC POLYMERS AND METHODS OF USE THEREOF
KR102332157B9 (en)	2022-12-27	EEG measuring device
UY30681A1 (en)	2008-07-03	PIRIDINAMIDE COMPOUNDS CONTAINING CARBOXI, PHARMACEUTICALLY ACCEPTABLE SALTS, PROCEDURES FOR THE PREPARATION OF THE SAME, COMPOSITIONS THAT CONTAIN THEM AND THEIR USES.
EP4156266A4 (en)	2023-11-22	MICRO-LED PACKAGE AND DISPLAY MODULE INCLUDING SAME
EP4204391A4 (en)	2025-01-01	LIPID COMPOUNDS AND LIPID DNANOPARTICLE COMPOSITIONS
EP4340857A4 (en)	2025-04-16	MODIFIED RELEASE FORMULATION COMPRISING WITHANOLIDES
EP4122483A4 (en)	2024-03-27	ORAL PHARMACEUTICAL COMPOSITION
EP4422605A4 (en)	2025-06-18	POEGMA-BASED LIPID NANOPARTICLES
DK1506179T3 (en)	2006-06-06	Benzoxazine derivatives as 5-HT6 modulators and their applications
EP4359076C0 (en)	2025-08-06	PHENYLPYRROLAMINOGUANIDINE SALTS AND FORMULATIONS
EP4354847A4 (en)	2024-07-24	SOLID STATE IMAGING DEVICE, IMAGING DEVICE AND DISTANCE MEASURING IMAGING DEVICE
EP4048142C0 (en)	2025-03-26	DYNAMIC VISUAL, VESTIBULAR AND SOMATOSENSORY CAPACITY MEASURING DEVICE
AU2021366254A9 (en)	2024-10-03	Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
EP4057249A4 (en)	2023-11-22	MEASURING SYSTEM AND DIAGNOSTIC SYSTEM
EP4110337A4 (en)	2024-03-20	ORAL DOSAGE FORM OF RIMÉGÉPANT, RAPIDLY DISPERSING
EP4308106A4 (en)	2025-02-26	MICROSPHERIC FORMULATIONS COMPRISING NALTREXONE AND METHODS OF PREPARATION AND USE THEREOF
EP4160703A4 (en)	2024-01-10	MICRO-LED AND DISPLAY MODULE INCLUDING SAME
HUP0302136A2 (en)	2003-09-29	Gallic acid derivatives and use for exploring endogenetic coagulation
EP4041451A4 (en)	2024-02-21	COMPOSITIONS COMPRISING QUINONE AND/OR QUINOL AND METHODS OF PREPARATION AND USE THEREOF
EP4228612A4 (en)	2024-10-09	ORAL CANNABINOID FORMULATION COMPRISING TOCOPHERYL PHOSPHATES AND LONG-CHAIN TRIGLYCERIDES OR LONG-CHAIN FATTY ACIDS
EP3926027A4 (en)	2022-11-09	GREASE BASE OIL AND GREASE COMPOSITION COMPRISING THEM
EP4488642A4 (en)	2026-03-25	TORQUE MEASURING DEVICE
EP4524544A4 (en)	2026-04-15	TRANSFER MEASURING METHOD AND TRANSFER MEASURING DEVICE